November 29, 2016 - By Linda Rogers · 0 Comments
The stock of Chiasma Incorporated (NASDAQ:CHMA) registered a decrease of 1.31% in short interest. CHMA’s total short interest was 1.33M shares in November as published by FINRA. Its down 1.31% from 1.35 million shares, reported previously. With 47,000 shares average volume, it will take short sellers 28 days to cover their CHMA’s short positions. The short interest to Chiasma Incorporated’s float is 11.25%. About 93,805 shares traded hands. Chiasma Inc (NASDAQ:CHMA) has declined 42.86% since April 26, 2016 and is downtrending. It has underperformed by 48.12% the S&P500.
Chiasma, Inc. is a biopharmaceutical company. The company has a market cap of $49.33 million. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. It currently has negative earnings. Using its Transient Permeability Enhancer technology platform, the Company is developing oral therapies.
Out of 3 analysts covering Chiasma (NASDAQ:CHMA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Chiasma has been the topic of 5 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating given on Monday, April 18 by William Blair. The stock of Chiasma Inc (NASDAQ:CHMA) has “Equal-Weight” rating given on Monday, April 25 by Barclays Capital. William Blair initiated the shares of CHMA in a report on Monday, August 10 with “Outperform” rating. As per Monday, August 10, the company rating was initiated by Barclays Capital. The firm has “Outperform” rating by Cowen & Co given on Monday, August 10.
Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Firm is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Firm has completed a Phase III clinical trial of its TPE platform product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.
More important recent Chiasma Inc (NASDAQ:CHMA) news were published by: Marketwatch.com which released: “Chiasma’s stock plummets 54% premarket after FDA response letter” on June 18, 2015, also Quotes.Wsj.com published article titled: “Chiasma Inc. CHMA (US: Nasdaq)”, Streetinsider.com published: “Chiasma, Inc. (CHMA) Affirms Receipt of FDA Complete Response Letter for …” on April 18, 2016. More interesting news about Chiasma Inc (NASDAQ:CHMA) was released by: Streetinsider.com and their article: “Chiasma, Inc. (CHMA) Names Mark J. Fitzpatrick as CEO” with publication date: September 30, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers